SCHEMBL3213248

SCHEMBL3213248

Cc1ccc(S(=O)(=O)n2ccc3c2CCCC3=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
PABPC1 P11940 1/20 0.46
TSHR P16473 1/20 0.46
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA4 P22748 1/20 0.45
CA9 Q16790 1/20 0.45
MAPT P10636 2/20 0.43
PKM P14618 3/20 0.43
HTT P42858 2/20 0.43
POLB P06746 1/20 0.43
RAPGEF4 Q8WZA2 1/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KCNN4 O15554 1/20 0.40
KCNA3 P22001 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266100 0.85 PARL (0.47) MMP2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL26980233 0.84 PKM (0.42) MMP2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3202921 0.78 ALDH1A1 (0.37) MMP2ALDH1A1CA1CA2PKM
SCHEMBL3202925 0.78 ALDH1A1 (0.37) MMP2ALDH1A1CA1CA2PKM
SCHEMBL20780052 0.78 PKM (0.46) MMP2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6755012 0.77 ALDH1A1 (0.59) MMP2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL30990322 0.77 PKM (0.43) MMP2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL24282440 0.76 PARL (0.50) MMP2ALDH1A1MEN1KMT2ATSHR
SCHEMBL5704726 0.76 MMP2 (0.51) MMP2ALDH1A1MEN1KMT2ACA1
SCHEMBL10854578 0.76 MMP2 (0.42) MMP2ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-61205288-A None JP disclosed
CN-119707774-A Bromination method of microwave-assisted 1,5,6, 7-tetrahydro-4H-indol-4-one derivative 浙江工业大学 2025-03-28 CN disclosed
US-20240002370-A1 PYRROLE-TYPE COMPOUNDS AND USES THEREOF FOR TREATING VIRAL INFECTIONS ENYO PHARMA (FR) 2024-01-04 US disclosed
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2022-07-07 US disclosed
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2022-07-07 US disclosed
US-11312723-B2 Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases THE ROCKEFELLER UNIVERSITY (US) 2022-04-26 US disclosed
US-11312723-B2 Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases THE ROCKEFELLER UNIVERSITY (US) 2022-04-26 US disclosed
US-20200369677-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2020-11-26 US disclosed
US-20200369677-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2020-11-26 US disclosed
EP-3716972-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES The Rockefeller University (US) 2020-10-07 EP disclosed
EP-1682502-A1 SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS Wyeth (US) 2006-07-26 EP disclosed
WO-2005047252-A1 SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2005-05-26 WO disclosed
US-20050101596-A1 Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands WYETH (US) 2005-05-12 US disclosed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed
JP-S61205288-A 4-CYANO-4,5,6,7-TETRAHYDROINDOLE DERIVATIVE AND PRODUCTION THEREOF SAGAMI CHEM RES CENTER 1986-09-11 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002370-A1 PYRROLE-TYPE COMPOUNDS AND USES THEREOF FOR TREATING VIRAL INFECTIONS PPIE, PYCR1, PIN1 MMP2 3205/4885ALDH1A1 1015/4885SMN1; SMN2 3121/4885
US-20200369677-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI, TFPI2, SERPINC1 MMP2 866/4885ALDH1A1 1832/4885SMN1; SMN2 4537/4885
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 MMP2 2271/4885ALDH1A1 1671/4885SMN1; SMN2 3536/4885
US-11312723-B2 Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases TFPI, TFPI2, SERPINC1 MMP2 866/4885ALDH1A1 1832/4885SMN1; SMN2 4537/4885
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI, TFPI2, SERPINC1 MMP2 866/4885ALDH1A1 1832/4885SMN1; SMN2 4537/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 MMP2 2271/4885ALDH1A1 1671/4885SMN1; SMN2 3536/4885
US-20050101596-A1 Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands HTR6, HTR5A, TPH1 MMP2 3642/4885ALDH1A1 1192/4885SMN1; SMN2 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.